Cytek Biosciences announces a new $50 million stock repurchase program, effective January 1, 2025.
Quiver AI Summary
Cytek Biosciences, Inc. has announced a new stock repurchase program authorized by its Board of Directors, allowing the company to buy back up to $50 million of its common stock starting January 1, 2025, following the expiration of an existing program. This new initiative will remain effective until December 31, 2025, unless adjusted by the Board. Repurchases will comply with SEC regulations and can occur through open market transactions or private negotiations, depending on various factors such as liquidity and market conditions. Cytek, a leader in cell analysis solutions based in Fremont, California, emphasizes that the program does not obligate the company to repurchase any specific amount of stock and may be modified or suspended at the company's discretion.
Potential Positives
- The approval of a new $50 million stock repurchase program indicates confidence by the Board of Directors in the company's financial health and future prospects.
- The continuation of stock repurchase programs can potentially enhance shareholder value by reducing the number of shares outstanding.
- The program signals to investors that the company has sufficient liquidity and cash flow to engage in share buybacks, which may be viewed positively by the market.
Potential Negatives
- The new stock repurchase program may signal a lack of profitable investment opportunities for the company, suggesting that it is returning capital to shareholders instead of pursuing growth.
- The lack of a specific commitment to the amount and timing of stock repurchases could create uncertainty for investors regarding the company's actual financial health and strategic intentions.
- The forward-looking statements included in the release highlight inherent uncertainties and risks, which may increase investor apprehension about the company's future performance.
FAQ
What is the new stock repurchase program approved by Cytek Biosciences?
Cytek Biosciences' Board approved a new stock repurchase program for up to $50 million, effective January 1, 2025.
How long will the repurchase program last?
The repurchase program will be in effect until December 31, 2025, unless extended or shortened by the Board.
What factors will influence the timing of stock repurchases?
The amount and timing of repurchases depend on liquidity, cash flow, market conditions, and compliance with legal requirements.
Are there any obligations tied to the stock repurchase program?
There is no obligation for Cytek to acquire a specific amount of common stock; the program may be modified or suspended at any time.
Where can I find more information about Cytek Biosciences?
More information about Cytek Biosciences and its products is available on their official website at www.cytekbio.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CTKB Hedge Fund Activity
We have seen 85 institutional investors add shares of $CTKB stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BROWN CAPITAL MANAGEMENT LLC removed 1,893,910 shares (-16.6%) from their portfolio in Q3 2024
- BLACKROCK, INC. added 1,421,869 shares (+8.3%) to their portfolio in Q3 2024
- NEW YORK STATE COMMON RETIREMENT FUND removed 860,618 shares (-29.2%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 755,881 shares (-79.9%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC removed 334,507 shares (-24.6%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 213,444 shares (+373.6%) to their portfolio in Q3 2024
- STATE STREET CORP added 194,369 shares (+4.9%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024. The new repurchase program is authorized to commence on January 1, 2025 and remain in effect until December 31, 2025 unless extended or shortened by the Board of Directors.
Any repurchases under the 2025 repurchase program will be made in the open market and/or in privately negotiated transactions and may be made from time to time or in one or more larger repurchases. The program will be conducted in compliance with the Securities and Exchange Commission's Rule 10b-18 and applicable legal requirements. The amount and timing of any repurchases made under the repurchase program will depend on a variety of factors, including available liquidity, cash flow and market conditions.
The program does not obligate the Company to acquire any particular amount of common stock, and the program may be modified or suspended at any time at the Company's discretion.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™ and Northern Lights™ systems and the Cytek Aurora CS cell sorter; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometer and imaging products under the Amnis
®
and Guava
®
brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts, including statements regarding our future activity, if any, under the share repurchase program, including the timing of any such repurchases, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed on November 7, 2024 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
